Now showing items 1-3 of 3

    • High Dose Intermittent Sorafenib Shows Improved Efficacy Over Conventional Continuous Dose in Renal Cell Carcinoma 

      Wang, Xiaoen; Zhang, Liang; Goldberg, S. Nahum; Bhasin, Manoj; Brown, Victoria; Alsop, David C.; Signoretti, Sabina; Mier, James W.; Atkins, Michael B.; Bhatt, Rupal Satish (BioMed Central, 2011)
      Background: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and ...
    • Increased Mobilisation of Circulating Endothelial Progenitors in von Hippel-Lindau Disease and Renal Cell Carcinoma 

      Zurita, A J; Norden-Zfoni, A; George, D; Heymach, J V; Bhatt, Rupal Satish; O'Neill, Allison Frances; Zhang, Liang; Wu, H.K.; Wen, Patrick Yung Chih; Sukhatme, Vikas Pandurang; Atkins, M.B. (Nature Publishing Group, 2011)
      Background: Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic ...
    • Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression 

      Bhasin, Manoj; Schor-Bardach, Rachel; Collins, Michael P.; Zhang, Liang; Wang, Xiaoen; Panka, David Joel; Putheti, Prabhakar; Signoretti, Sabina; Alsop, David C.; Libermann, Towia Aron; Atkins, Michael B.; Mier, James W.; Goldberg, S. Nahum; Bhatt, Rupal Satish (Public Library of Science, 2011)
      Purpose: Resistance to antiangiogenic therapy is an important clinical problem. We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic ...